添付書類3-1:非採用文献リスト(A) 英文50+和文11=61文献
No Auther Title Journal Volumes Issue Pages Year
A1 Homma Y, Akaza H, Okada K, Yokoyama M, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y; Prostate Cancer Study Group. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. Int J Urol 11 4 218-24 2004
A2 Namiki S, Saito S, Tochigi T, Kuwahara M, Ioritani N, Yoshimura K, Terai A, Koinuma N, Arai Y. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life. Int J Urol 12 2 173-81 2005
A3 Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol 12 7 662-7 2005
A4 北村浩二,増田健人,中村晃和,沖原宏治,浮村理,河内明宏,三木恒治. 前立腺全摘除術を施行した検診発見前立腺がんの治療成績. 日本がん検診・診断学会誌 11 2 94-7 2004
A5 山本巧,伊藤一人,大井勝,武智浩之,坂西理恵,黒川公平,鈴木和浩,山中英壽. 前立腺特異抗原(PSA)による前立腺がん検診と精度管理. 日本がん検診・診断学会誌 11 2 1937-9 2004
A6 平野恭弘,古瀬洋,佐藤崇,鈴木泰介,福田健,北川元昭,阿曽佳郎. 藤枝市における前立腺癌検診8年間の結果からみた検診間隔の検討. 日本腎泌尿器疾患予防医学研究会誌 12 1 38-40 2004
A7 古賀寛史,山口秋人,宮崎良春,辻祐治,太田康弘,内藤誠二. 前立腺癌PSA単独検診の問題点 ―2次検診PSA基準値未満例について― 日本腎泌尿器疾患予防医学研究会誌 12 1 44-6 2004
A8 北村浩二,増田健人,沖原宏治,浮村理,河内明宏,三木恒治. 検診で発見された前立腺癌のホルモン治療成績. 日本腎泌尿器疾患予防医学研究会誌 12 1 1961-2 2004
A9 内藤 誠二,小藤 秀嗣,熊澤 浄一,尾本 徹男,伊東 健治,畑地 康助,清水 保夫,横山 譲二,永芳 弘之,鷺山 和幸,長谷川 淑博,森田 一喜朗,太田 康弘,箕田 薫,本村 精二. 福岡県におけるドック前立腺検診の現状と問題点. 日本泌尿器科学会雑誌 84 7 1227-35 1993
A10 加藤司顯,多武保光宏,吉松正,太田雅也,金城真実,野田治久,渡辺和吉,宮田晃臣,村田明弘,三浦一郎,米田龍生,吉井将人,桶川隆嗣,小島美保,佐山孝,奴田原紀久雄,東原英二. 前立腺癌の早期診断における検診の意義. 日本泌尿器科学会雑誌 92 1 23-9 2001
A11 金山博臣,香川征,宇都宮正登,川島周,武久一郎,炭谷晴雄,横関秀明. 徳島市前立腺がん検診について(第一報) : 平成13年度初年度の結果に対する解析. 日本泌尿器科学会雑誌 95 3 596-603 2004
A12 Madalinska JB, Essink-Bot ML, de Koning HJ, Kirkels WJ, van der Maas PJ, Schröder FH. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 46 2 87-97 2001
A13 Hugosson J, Aus G, Lilja H, Lodding P, Pihl C.G, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 169 5 1720-3 2003
A14 Hugosson J, Aus G, Lilja H, Lodding P, Pihl C-G. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100 7 1397-405 2004
A15 Roobol MJ, van der Cruijsen IW, Schröder FH. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam). Urol 63 5 892-7 2004
A16 Martin E, Lujan M, Sanchez E, Herrero A, Paez A, Berenguer A. Final results of a screening campaign for prostate cancer. Eur Urol 35 1 26-31 1999
A17 Hoedemaeker RF, Kranse R, Rietbergen JBW, Boeken Kruger AE, Schröder FH, Van der Kwast TH. Evaluation of prostate needle biopsies in a population-based screening study: the impact of borderline lesions. Cancer 85 1 145-52 1999
A18 Crawford ED, Pinsky PF, Chia D, Kramer BS, Fagerstrom RM, Andriole G, Reding D, Gelmann EP, Levin DL, Gohagan JK. Prostate specific antigen changes as related to the intial prostate specific antigen: date from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Urol 175 4 1286-90 2006
A19 Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119 9 914-23 1993
A20 Draisma G, De Koning HJ. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 92 Suppl 2 106-11 2003
A21 Hugosson J, Aus G, Bergdahl S, Fernlund P, Frosing R, Lodding P, Pihl CG, Lilja H. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 92 Suppl 2 39-43 2003
A22 Postma R, Roobol M, Schroder FH, van der Kwast TH. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years. Cancer 100 5 968-75 2004
A23 Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer. Int J Cancer 109 3 455-60 2004
A24 Steiner H, Moser P, Hager M, Berger AP, Klocker H, Spranger R, Rogatsch H, Bartsch G, Horninger W. Clinical and pathologic features of prostate cancer detected after repeat false-negative biopsy in a screening population. Prostate 58 3 277-82 2004
A25 Nicholson PW, Harland SJ. Survival prospects after screen-detection of prostate cancer. BJU Int 90 7 686-93 2002
A26 Lewis JS Jr, Vollmer RT, Humphrey PA. Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. Am J Clin Pathol 118 3 442-50 2002
A27 Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, Baschet F, Cussenot I, L'Her J, Berthon P, Mangin P, Cussenot O, Morin JF, Fournier G. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 168 2 483-7 2002
A28 Uozumi J, Tokuda Y, Fujiyama C, Takagi N, Meiri H, Kuratomi K, Nakamura K, Ichigi Y, Yoshinaga H, Kinoshita N, Masaki Z. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program. Int J Urol 9 6 334-9 2002
A29 Finne P, Auvinen A, Aro J, Juusela H, Maattanen L, Rannikko S, Hakama M, Tammela TL, Stenman UH. Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol 41 6 619-26; discussion 626-7 2002
A30 Makinen T, Tammela TL, Stenman UH, Maattanen L, Rannikko S, Aro J, Juusela H, Hakama M, Auvinen A. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 20 11 2658-63 2002
A31 Hoedemaeker RF, van der Kwast TH, Boer R, de Koning HJ, Roobol M, Vis AN, Schroder FH. Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst 93 15 1153-8 2001
A32 Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination. Urology 57 1 83-90 2001
A33 Roberts RO, Bergstralh EJ, Lieber MM, Jacobsen SJ. Digital rectal examination and prostate-specific antigen abnormalities at the time of prostate biopsy and biopsy outcomes, 1980 to 1997. Urology 56 5 817-22 2000
A34 Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 284 11 1399-405 2000
A35 Uchida K, Takeshima H, Akaza H, Ono Y. Screening for prostate cancer using prostate-specific antigen alone as a first-line checkup parameter: results of the health checkup system. Jpn J Clin Oncol 30 2 95-100 2000
A36 Smith DS, Carvalhal GF, Schneider K, Krygiel J, Yan Y, Catalona WJ. Quality-of-life outcomes for men with prostate carcinoma detected by screening. Cancer 88 6 1454-63 2000
A37 Horninger W, Reissigl A, Rogatsch H, Volgger H, Studen M, Klocker H, Bartsch G. Prostate cancer screening in Tyrol, Austria: experience and results. Eur Urol 35 5-6 523-38 1999
A38 Zappa M, Ciatto S, Bonardi R, Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 9 12 1297-300 1998
A39 Di Matteo L, Di Matteo R. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates. Eur J Health Econ 6 4 298-308 2005
A40 Bangma CH, Kranse R, Blijenberg BG, Schroder FH. Free and total prostate-specific antigen in a screened population. Br J Urol 79 5 756-62 1997
A41 Helgesen F, Holmberg L, Johansson JE, Bergstrom R, Adami HO. Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst 88 17 1216-21 1996
A42 Parkes C, Wald NJ, Murphy P, George L, Watt HC, Kirby R, Knekt P, Helzlsouer KJ, Tuomilehto J. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. BMJ 311 7016 1340-3 1995
A43 Reissigl A, Pointner J, Horninger W, Ennemoser O, Strasser H, Klocker H, Bartsch G. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Urology 46 5 662-5 1995
A44 Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 15 1214-20 1995
A45 Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, Zappa M. Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate-specific antigen. Tumori 81 4 225-9 1995
A46 Gustafsson O, Theorell T, Norming U, Perski A, Ohstrom M, Nyman CR. Psychological reactions in men screened for prostate cancer. Br J Urol 75 5 631-6 1995
A47 Catalona WJ, Hudson MA, Scardino PT, Richie JP, Ahmann FR, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 152 6 Pt 1 2037-42 1994
A48 Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schroder FH. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience. Can J Urol 12 Suppl 2 16-20 2005
A49 Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 152 5 Pt 2 1737-40 1994
A50 Bretton PR. Prostate-specific antigen and digital rectal examination in screening for prostate cancer: a community-based study. South Med J 87 7 720-3 1994
A51 Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. Cancer 72 5 1701-8 1993
A52 Kramer BS, Gohagan J, Prorok PC, Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71 Suppl 2 589-93 1993
A53 Gerber GS, Thompson IM, Thisted R, Chodak GW. Disease-specific survival following routine prostate cancer screening by digital rectal examination. JAMA 296 1 61-4 1993
A54 Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 173 4 1116-20 2005
A55 Coory MD, Baade PD. Urban-rural differences in prostate cancer mortality, radical prostatectomy and prostate-specific antigen testing in Australia. Med J Aust 182 3 112-5 2005
A56 Sennfalt K, Sandblom G, Carlsson P, Varenhorst E. Costs and effects of prostate cancer screening in Sweden--a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 38 4 291-8 2004
A57 Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics 5 4 603-13 2004
A58 Gupta A, Roehrborn CG. Verification and incorporation biases in studies assessing screening tests: prostate-specific antigen as an example. Urology 64 1 106-11 2004
A59 Smith RP, Malkowicz SB, Whittington R, VanArsdalen K, Tochner Z, Wein AJ. Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med 164 11 1227-30 2004
A60 Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P, Bartsch G. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 5 3 220-5 2004
A61 Gavin A, McCarron P, Middleton RJ, Savage G, Catney D, O'Reilly D, Keane PF, Murray LJ. Evidence of prostate cancer screening in a UK region. BJU Int 93 6 730-4 2004

添付書類3-2:非採用文献リスト(B) 英文19+和文2=21文献
No Auther Title Journal Volumes Issue Pages Year
B1 山本巧(群馬大学 泌尿器科),伊藤一人,大井勝,久保田裕,山中英壽 前立腺がん集団検診におけるPSA単独検診とPSA・直腸診併用検診の比較 日本がん検診・診断学会雑誌 8 2 63-3 2001
B2 中西弘之(京都府立医科大学 泌尿器科),中尾昌宏,野本剛史,三木恒治,中川修一,北村浩二,渡辺泱 前立腺がん検診におけるカットオフ値としてのPSA年齢別基準値の検討 日本泌尿器科学会雑誌 90 11 853-8 1999
B3 Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis Family Practice 16 6 621-6 1999
B4 Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttanen L, Auvinen A. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen Clin Cancer Res 9 7 2435-9 2003
B5 Aus G, Becker C, Franzen S, Lilja H, lodding P, Hugosson J. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio Eur Urol 45 2 160-5 2004
B6 De Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schröder FH. Overall and Disease-Specific Survival of Patients with Screen-Detected Prostate Cancer in the European Randomized Study of Screening for Prostate Cancer, Section Rotterdam Eur Urol XXX     2006
B7 Rietbergen JBW, Hoedemaeker RF, Boeken Kruger AE, Kirkels WJ, Schröder FH. The changing pattern of prostate cancer at the time of diagnosis: characteristics of screen detected prostate cancers in a population-based screening study. J Urol 161 4 1192-8 1999
B8 Berenguer A, Lujan M, Paez A, Santonja C, Pascual T. The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer. BJU Int 92 Suppl 2 33-8 2003
B9 Quaglia A, Vercelli M, Puppo A, Casella C, Artioli E, Crocetti E, Falcini F, Ramazzotti V, Tagliabue G; Prostate Working Group. Prostate cancer in Italy before and during the 'PSA era': survival trend and prognostic determinants. Eur J Cancer Prev 12 2 145-52 2003
B10 Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL. Urology 61 4 760-4 2003
B11 Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, Severi G, Robertson C, Boyle P; Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 3 417-24 2001
B12 加藤 司顯,多武保 光宏,吉松 正,太田 雅也,金城 真実,野田 治久,渡辺 和吉,宮田 晃臣,村田 明弘,三浦 一郎,米田 龍生,吉井 将人,桶川 隆嗣,小島 美保,佐山 孝,奴田原 紀久雄,東原 英二. 前立腺癌の早期診断における検診の意義. 日本泌尿器科学会雑誌 92 1 23-9 2001
B13 Beemsterboer PM, Kranse R, de Koning HJ, Habbema JD, Schroder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 84 4 437-41 1999
B14 Meyer F, Moore L, Bairati I, Fradet Y. Quebec prostate cancer mortality dropped in 1996. Cancer Prev Control 2 4 163-6 1998
B15 Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, Kranse R. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 90 23 1817-23 1998
B16 Aus G, Damber JE, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med 165 16 1857-61 2005
B17 Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schroder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 15 6 339-45 1997
B18 Schroder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam. J Urol 174 2 489-94; discussion 493-4 2005
B19 Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, Kramer BS, Reding D, Church TR, Grubb RL, Izmirlian G, Ragard LR, Clapp JD, Prorok PC, Gohagan JK; PLCO Project Team. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 6 433-8 2005
B20 Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94 10 1361-8 2006
B21 Makinen T, Tammela TL, Stenman UH, Maattanen L, Aro J, Juusela H, Martikainen P, Hakama M, Auvinen A. Second round results of the Finnish population-based prostate cancer screening trial. Clin Cancer Res 10 7 2231-6 2004

添付書類3-3:非採用文献リスト(C) 英文12+和文0=12文献
No Auther Title Journal Volumes Issue Pages Year
C1 de Vries SH, Raaijmakers R, Kranse R, Blijenberg BG, Schröder FH. Prostate cancer characteristics and prostate specific antigen changes in screening detected patients initially treated with a watchful waiting policy. J Urol 172 6 Pt 1 2139-6 2004
C2 van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van dr Kwast TH, Schröder FH. Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomised study of Screening for Prostate Cancer, section Rotterdam. J Urol 174 1 121-5 2005
C3 Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH. Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance. Eur Urol 50 3 475-82 2006
C4 Rietbergen JWB, Boeken Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: Clinical and pathological features of detected cancers. J Urol 160 6 Pt 1 2121-5 1998
C5 Vis AN, Boerma MO, Ciatto S, Hoedemaeker RF, Schroder FH, van der Kwast TH. Detection of Prostate Cancer: A Comparative Study of the Diagnostic Efficacy of Sextant Transrectal versus Sextant Transperineal Biopsy. Urol 56 4 617-21 2000
C6 Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, Cruijsen-Koeter I, van der Kwast TH, Schroder FH. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 66 4 625-31 2006
C7 渡辺真,斉藤雅人,渡邊泱. 前立腺癌のスクリーニングにおける経直腸的超音波断層法の診断精度. 泌尿器科紀要 42 10 763-6 1996
C8 Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk. Prostate 64 3 240-5 2005
C9 Ciatto S, Gervasi G, Bonardi R, Frullini P, Zendron P, Lombardi C, Crocetti E, Zappa M. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 41 3 411-5 2005
C10 Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schroder FH, van der Kwast TH. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years. Cancer 103 4 708-16 2005
C11 Brenner H, Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 23 3 441-7 2005
C12 Roemeling S, Roobol MJ, Gosselaar C, Schroder FH. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Prostate 66 10 1076-81 2006